Osteonecrosis of the jaw (ONJ) is a serious adverse drug event that was initially reported with intravenous bisphosphonates (BPs) and more recently with other classes of drugs such as receptor activator of NF-kB ligand (RANKL) inhibitor, antiangiogenic agents, and mammalian target of rapamycin (m-TOR) inhibitors. The purpose of this study is to analyze the ONJ cases and the associated drugs in the US Food and Drug Administration's adverse event reporting system (FAERS). The FAERS database was queried for the adverse drug events reported from the first quarter of 2010 to the first quarter of 2014. The reporting odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each queried drug. A total of 17,119 unique ONJ cases were identified. In the overall analysis, the drugs with the highest reporting ORs were BPs: pamidronate (OR ¼ 498.9), zoledronate (OR ¼ 171.7), and alendronate (OR ¼ 63.6), whereas denosumab had lower ORs than all the BPs except for etidronate. The antiangiogenic and m-TOR inhibitors had the lowest ORs. In cancer patients who were treated for prevention of skeletal-related events (SREs), the reporting ORs for zoledronate and denosumab were 125.2 and 4.9, respectively. In patients with osteoporosis, the ORs were 1.1 (1.0-1.18) for zoledronate and 0.63 (0.56-0.70) for denosumab, respectively. Our analysis of the FAERS database showed that the intravenous BPs were associated with the highest risk for ONJ, RANKL inhibitor was associated with risk comparable to BPs used for osteoporosis such as etidronate, and the antiangiogenic agents and m-TOR inhibitors were associated with the lowest risk for ONJ. The high risk for ONJ with zoledronate and denosumab was mainly observed in those who were treated for prevention of SREs, whereas there was limited evidence for such risk in those who were treated for osteoporosis.
Introduction
O steonecrosis of the jaw (ONJ) is a rare and serious disease, which manifests itself as areas of necrotic jaw bone (maxilla and mandible) that are exposed to the oral cavity and show no signs of healing after at least 8 weeks of recognition or identification. From a historical perspective, ONJ goes back to the 18th century, where cases of "phossy jaw" were first described among workers exposed to phosphorus vapors. With the advent of bisphosphonates (BPs), new cases of ONJ started surfacing again in 2003, primarily in cancer patients with metastatic bone disease treated with intravenous bisphosphonates such as pamidronate and zoledronate for the prevention of skeletal-related events (SREs).
(1) Because of the growing use of intravenous BPs for the prevention of SREs, several case reports were subsequently published in the medical literature correlating the incidence of ONJ with the use of BPs. As a consequence, the term BP-related ONJ or bisphosphonate-related osteonecrosis of the jaw (BRONJ) was introduced. The severity of this condition prompted the American Society for Bone and Mineral Research (ASBMR) and the American Association of Oral and Maxillofacial Surgeons (AAOMS) to develop in 2007 the following diagnostic criteria to distinguish BRONJ from other types of ONJ, such as spontaneous ONJ or osteoradionecrosis of the jaw, current or previous treatment with a BP: exposed bone in the maxillofacial region that persisted for at least 8 weeks, and finally no history of radiation to the jaws. (2) BPs constitute the mainstay of therapy for the prevention of SREs in the setting of solid tumors and multiple myelomas, as well as for the treatment of osteoporosis and metabolic bone diseases. Currently in the United States, there are five BPs approved by the FDA for the aforementioned indications: alendronate, risendronate, ibandronate, pamidronate, and zolendronate with the last two (pamidronate and zolendronate) widely prescribed for the prevention of skeletal complications in patients with metastatic bone disease. It is worth noting that the incidence of ONJ varies among BPs depending on route of administration, potency, total dose, and length of exposure. (3) (4) (5) Findings from retrospective studies demonstrated that approximately 95% of the reported ONJ cases were observed in patients receiving parenteral BPs (mainly zolendronate) for the prevention of SREs, whereas the remaining 5% occurred in patients treated with oral BPs for osteoporosis. (6) Such findings are not surprising, considering the substantially higher doses and the greater frequency of exposure to parenteral BPs in the setting of metastatic bone disease in comparison with those of oral BPs used for the treatment of osteoporosis. (7) In addition to BP use, there are other risk factors that could potentially trigger ONJ, such as dental extraction, periodontal disease, denture trauma, chemotherapy, and corticosteroid use. In light of the new published cases implicating denosumab (a monoclonal antibody targeting RANK ligand), some antiangiogenesis drugs such as bevacizumab and sunitinib (commonly used in solid tumors), and mammalian target of rapamycin (m-TOR) inhibitor, everolimus in the pathogenesis of ONJ, (8) (9) (10) (11) (12) the term BRONJ seems rather obsolete and should no longer be restricted to BPs. In the 2014 position paper on ONJ, the AAOMS replaced the term BRONJ with medication-related osteonecrosis of the jaw or simply MRONJ to reflect the current evidence supporting the incidence of ONJ with the use of RANKL inhibitors and antiangiogenic agents. (13) The FDA's adverse event reporting system (FAERS) is a database that contains information on adverse event reports submitted to the FDA, and is designed to support the postmarketing surveillance of the MedWatch program. For the reporting of ONJ, the Medical Dictionary for Regulatory Activities (MedDRA) preferred term "osteonecrosis of jaw" was established in March 2010 (www.meddra.org). The objectives of this study were to describe the number of ONJ reported in FAERS, and to estimate the reporting odds ratios (OR) for ONJ owing to medications known to be associated with ONJ: BPs, RANKL inhibitors, antiangiogenic drugs, and m-TOR inhibitors.
Materials and Methods

Data
The FAERS database was queried from the first quarter (Q1) of 2010 through Q1 of 2014, which are all the quarters with data available. The main reasons for limiting our search query to this period were that ONJ cases reported to FAERS before March 2010 were not reviewed by safety analysts, and most importantly some of these cases did not provide critical detail to satisfy the criteria set forth by the AAOMS for establishing a definitive diagnosis of ONJ. The search terms for ONJ were "Osteonecrosis of the jaw" and "OSTEONECROSIS OF JAW." The drugs queried included the four drug classes reported to be associated with ONJ: BPs, antiangiogenic drugs, RANKL inhibitors, and m-TOR inhibitors. Both brand names and generic names were used for each drug. Demographic variables such as age, sex, region, and the indications for drug treatment (cancer or osteoporosis) were also collected from the FAERS database.
Statistical analysis
Continuous variables were presented as means and standard deviations, and categorical variables were presented as frequencies and percentages as appropriate. The reporting ORs and 95% confidence intervals (CIs) were also calculated as previously reported. (14, 15) Briefly, for each drug and ONJ combination, a 2 by 2 contingency table was constructed indicating four groups of individuals: treated with this drug and had ONJ; treated with this drug but did not have ONJ; not treated with this drug and had ONJ; not treated with this drug and did not have ONJ. All analyses were performed in SAS version 9.3 (SAS Institute, Cary, NC, USA). The OR estimates and 95% CIs were calculated using "proc freq" procedure.
Results
The FAERS system was queried based on the adverse events reported between the first quarter of 2010 and the first quarter of 2014. A total of 3,310,491 unique adverse events were reported in the system, including 17,119 unique ONJ cases. The numbers of ONJ cases by quarter are presented in Fig. 1 . There were more than 1000 ONJ cases reported for each quarter between Q2 of 2010 and Q2 of 2012. Afterwards, the number of cases reported dropped dramatically.
Demographics and relevant drug use of the ONJ cases
The demographics of all the 17,119 ONJ cases were reported in Table 1 . Within the ONJ cases with age and sex information reported, 69.7% were females and 30.3% were males, and the average age was 62 years. Around 70% of these cases were reported from the United States. For the 11,690 patients with relevant indications reported, 59% of these ONJ cases were treated to prevent SREs, and 41% of the ONJ cases were taking these medications for the treatment or prevention of osteoporosis. Patients with indications for both SRE and osteoporosis were not included in this analysis. Among those cases taking these drugs for prevention of SRE, 24% had breast cancer, 20% had multiple myeloma, 9% had prostate cancer, 3.7% had renal cancer, 1.3% had lung cancer, and 3% had metastases to bone owing to other cancer types. 
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Drugs associated with ONJ The medications reported for these ONJ cases were also listed in Table 1 . Overall, the majority of the identified ONJ cases were treated with bisphosphonates: zoledronate (67.1%), alendronate (42.7%), or pamidronate (30.7%). A total of 1184 cases (6.9%) were reported to be on the RANKL inhibitor, denosumab. Approximately 7% were on antiangiogenic agents such as bevacizumab (4.1%), sunitinib (2.4%), or sorafenib (0.5%), and a few cases were on pazopanib or axitinib. Interestingly, 84 and 28 ONJ cases were associated with m-TOR inhibitors everolimus and temsirolimus, respectively. The number of reported cases by quarter was presented in figure 2 for drugs with more than 100 cases reported. Zoledronate was the drug with the highest frequency of ONJ reported, followed by pamidronate and alendronate. Overall, there was a decrease in ONJ after the second quarter of 2012.
Among these ONJ cases that were treated for the SREs, 89.5% occurred with zoledronate, 36% with pamidronate, 6.4% with denosumab, 5.7% with bevacizumab, and 4.2% with sunitinib. Among the ONJ cases with the indication of osteoporosis, 84.5% were on alendronate, 17% were on zoledronate, 12.6% were on ibandronate, 11.9% on risedronate, and 7.9% on denosumab (Table 1) .
The estimated reporting ORs for each of the individual drugs associated with ONJ are summarized in Because zoledronate and denosumab could be used for the prevention of SREs and in patients with osteoporosis, we separately calculated the reporting ORs of these two drugs in these two settings. In cancer patients who were treated for prevention of SREs, the ORs for zoledronate and denosumab were 125.2 (95% CI: 115.7-135.8, p < 0.0001) and 4.9 (95% CI: 4.4-5.4, p < 0.0001), respectively. In patients with osteoporosis, the ORs were 1.1 (95% CI: 1.0-1.18, p ¼ 0.029) for zoledronate and 0.63 (95% CI: 0.56-0.70, p < 0.0001) for denosumab, respectively.
Discussion
We identified 17,119 unique ONJ cases in the FDA's FAERS system based on the reports from the first quarter of 2010 to the first quarter of 2014, and we further broke down those cases into two main categories: ONJ cases in the setting of SRE prevention and ONJ cases in the osteoporosis setting. This is the first study to analyze all four classes of drugs associated with ONJ (BPs, RANKL inhibitor, antiangiogenic agents, and m-TOR inhibitors) and calculate the reporting OR for each individual medication belonging to one of these four drug classes. We found that most ONJ cases reported in the setting of SRE prevention occurred with the intravenous BPs, pamidronate and zoledronate, whereas ONJ cases in the osteoporosis setting were mostly with alendronate. The fact that the total percentages of these medications added up to more than 100% indicated that some patients might have been on multiple drugs or might have been switched from one drug to another. What is unique to our study is that we were able to show that the association between ONJ risk and the use of the RANKL inhibitor, denosumab, is lower than that of either IV BPs or alendronate. Furthermore, this is the first study to show that m-TOR inhibitors such as temsirolimus and everolimus were also associated with the risk for ONJ. Our analysis of the FAERS database suggested that the prevalence of ONJ varies, depending on the type of malignancy with metastatic breast cancer and multiple myeloma having the highest ONJ rates. Such findings were consistent with those from the MD Anderson registry study conducted by Hoff and colleagues.
The increased risk for ONJ that we noted with zoledronate and denosumab occurred primarily in patients who received the aforementioned drugs for the prevention of SREs. Furthermore, the likelihood for such a risk with either drug was lower in the osteoporosis setting, and this is supported by other studies interrogating the risks of ONJ among patients with osteoporosis. (16) (17) (18) Prospective data have demonstrated that the risks of ONJ with zoledronate and denosumab were almost comparable. (19, 20) Our results, on the other hand, suggested a lower risk (or lower odds ratio) for denosumab-induced ONJ, particularly in the osteoporosis setting, which could be ascribed to either undetected ONJ (especially if patients presented with stage 0 ONJ, defined as no areas of exposed bone as per the latest AAOMS criteria), and thereby underdiagnosis of ONJ with denosumab, or development of ONJ shortly after denosumab discontinuation, which might have resulted in labeling such patients as ONJ patients-not on denosumab, ie, non-drug-induced ONJ in the FAERS database.
The underlying mechanisms through which antiresorptive agents (BPs and denosumab), antiangiogenic drugs, and m-TOR inhibitors cause ONJ have not been fully elucidated yet.
Although this topic is beyond the scope of this article or study, it is important to point out that several explanations have been proposed. (21) By virtue of their antiresorptive properties, BPs and denosumab impair the bone remodeling process via inhibition of osteoclast activity, as well as induction of cell apoptosis. (22) In addition, formation of new blood vessels, mediated through vascular endothelial growth factor (VEGF) is considered an essential component of bone remodeling; therefore, disruption of this critical step by BPs may also predispose patients to ONJ development. (23) Our analyses of the FAERS system clearly suggest that there is a relationship between the incidence of ONJ and use of angiogenesis inhibitors, such as bevacizumab, sunitinib, pazopanib, and others. Accordingly, this adverse event is no longer linked to bisphosphonates or denosumab only.
Similar to what the study by Fusco and colleagues reported, (24) we noticed a decrease in the number of ONJ cases (overall event rates and rates for each drug) in year 2012, particularly after the 3rd quarter. The decline in ONJ rates is probably attributed to the following underlying factors: the publication of several case series or case reports worldwide that brought this drug-induced adverse effect into the spotlight, the presence of standardized criteria for ONJ diagnosis, and finally the increasing awareness of the risk for ONJ among health care providers brought about by the development and release of consensus guidelines and position papers advocating dental screening and the institution of appropriate measures before the initiation of antiresportive drugs in patients at risk for developing medication-related osteonecrosis of the jaw (MRONJ). The latest of these is the 2014 update of the position paper (13) crafted by the AAOMS in 2009. Interestingly, we found that approximately 70% of the reported ONJ cases were females. This finding was a bit surprising initially and could not be explained solely by the percentage of ONJ cases that occurred after the use of IV BPs for bone involvement (25) secondary to metastatic breast cancer (24%). What might have contributed to the high prevalence of ONJ among females was the high percentage of females (90%) with ONJ receiving oral BPs for osteoporosis.
It is worthwhile to mention that during our search of the FAERS database, we were able to identify a single adverse event report of drug-induced ONJ linked to the use of vandetanib, which is one of the available treatment options for locally advanced or metastatic medullary thyroid cancer. From a mechanistic standpoint, vandetanib is a multityrosine kinase receptor inhibitor, ie, blocks vascular endothelial growth factor receptors (VEGFR) and epidermal growth factor receptors (EGFR). Hence, the possibility that vandetanib is associated with ONJ seems rather plausible. Nonetheless, not a single case of ONJ was recorded in all of the clinical trials that sought to evaluate the efficacy and safety of vandetanib in the setting of metastatic thyroid cancer. In light of these data, a causal relationship between vandetanib and the risk of ONJ is difficult to establish at this point. Accordingly, close vigilance is warranted so as not to overlook the possibility of vandetanibinduced ONJ.
It is important to recognize that there are limitations to the approach of using the FAERS system. In essence, reporting an adverse event is voluntary and is not restricted to health care providers, ie, consumers can also submit an adverse event report. Because of the fact that only ONJ cases reported to the system can be identified, it is not possible to estimate the true incidence of ONJ in individuals taking these medications. Hence, epidemiological studies are warranted to determine the incidence rate. Second, because many ONJ patients were treated with multiple drugs known to be associated with ONJ, it is rather difficult to identify the offending drug or determine whether ONJ was the consequence of multiple drug use. Among the FAERS database shortcomings is the lack of some specific information that could be of great value for this type of analysis such as: limited information on indication for drug use (metastatic setting versus osteoporosis); lack of data on the route of administration as in the case of ibandronate, which is available in both oral and parenteral forms; and most importantly the duration of treatment. Based on the results from The PROBE (Predicting Risk of Osteoporosis with Bisphosphonates) study, the likelihood of ONJ development with oral bisphosphonates changed over time where the risk increased considerably beyond 4 years of therapy. (16) Of note, we were not able to substantiate this finding because such information is not available in FAERS. Nevertheless, FAERS provided valuable information in terms of odds ratios of the relevant drugs classes.
In conclusion, our analysis of the FAERS system showed that the intravenous BPs had the highest risk for drug-induced ONJ. Additionally, the RANKL inhibitor, denosumab, had an ONJ risk comparable to that of the BPs, which are used for treatment of osteoporosis, such as ibandronate, etidronate, and risedronate, whereas the antiangiogenic agents and m-TOR inhibitors were associated with the lowest risk for ONJ. Finally, the high risk for ONJ in zoledronate and denosumab was mainly observed in those who were treated for prevention of SREs, whereas there was limited evidence for such risk in those who were treated for osteoporosis.
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